2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

A Korean case of Fragile X-associated mild ataxia without tremor

WW. Lee, BK. Kim, O. Kwon, JM. Park, JJ. Lee, K. Kang (Seoul, Republic of Korea)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

A life-threatening case of Anti-IgLON5 disease

M. Filidei, N. Tambasco, F. Paolini Paoletti, S. Simoni, E. Brahimi, G. Cappelletti, P. Nigro, P. Calabresi (Perugia, Italy)

Choreas (Non-Huntington’s Disease)  ·  Les Muses, Level 3

1:45pm-3:15pm

A Multiple Ascending-Dose Study of LY3154207, A Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

K. Biglan, D. Wilbraham, K. Svensson, M. Tsai, W. Kielbasa (Indianapolis, IN, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

A novel intronic pentanucleotide TTTGA repeat insertion in SAMD12 causes familial cortical myoclonic tremor with epilepsy type 1

ZD. Cen, Y. Chen, S. Chen, XH. Chen, B. Wang, F. Xie, OY. Zhiyuan, ZW. Jiang, AS. Fu, B. Hu, HM. Yin, X. Qiu, F. Yu, XP. Du, WC. Has, YX. Liu, HT. Wang, DH. Yang, LB. Wang, CY. Liu, JF. Xiao, BR. Zhang, W. Luo (Hangzhou, China)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

A novel intronic variant in MAPT causes FTLD-parkinsonism: Implications for regulatory mechanism of MAPT pre-mRNA splicing

P. Gonzalez-Latapi, B. Bustos, D. Larson, L. Kinsley, N. Siddique, T. Siddique, T. Simuni, E. Bigio, S. Lubbe, R. de Silva, D. Krainc, N. Mencacci (Chicago, IL, USA)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

A novel p.Trp42Arg REEP1 mutation associated with autosomal recessive Distal spinal muscular atrophy with vocal cord and diaphragmatic paralysis

R. Kaiyrzhanov, R. Maroofian, M. Behnam, M. Salehi, V. Salpietro, H. Houlden (London, United Kingdom)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

A novel TGM6 heterozygous mutation in a patient with cerebellar ataxia

A. Manini, T. Bocci, E. Monfrini, D. Ronchi, M. Vizziello, G. Franco, A. de Rosa, F. Sartucci, A. Di Fonzo (Milan, Italy)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results

T. Simuni (Chicago, IL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3